top of page
DNA_edited.jpg
New topics TransChromosomics

2023.04.05

Notice of Publication of Article on Human Anti-EpCAM Antibody Obtained Using Fully Human Antibody-Producing Mice and ADC Technology
(The article cite is here.)

2022.04.06

Notice of Publication of Article on Generation and Evaluation of Fully Human Antibody-Producing Mice (TC-mAbTM Mice)

(The article cite is here, and the Tottori University release page is here.)

2021.04.13

Trans Chromosomics, Inc. announces approval of a Japanese patent for TC-mAbTM mice (fully human antibody-producing mice)

2021.04.13

Trans Chromosomics, Inc. announces approval of a Japanese patent for a new drug-metabolizing enzyme induction evaluation method capable of inducing and predicting pharmacokinetics of humans

2020.11.25

Trans Chromosomics, Inc. agreed with Precision Antibody, Inc. which has the world-class antibody acquisition technology to expand our global business for acquiring therapeutic seeds of human antibody in 60 days using our fully human antibody producing mice and supplying them to pharmaceutical companies, etc.. (brochure #1, #2)

2020.09.16

Identification of prophylactic and therapeutic human antibody against new coronavirus (SARS-CoV-2)

2020.07.17

A group of associate professor Yasuhiro Kazuki of Chromosome Engineering Research Center of Tottori University, collaborator of Trans Chromosomics, Inc., succeeded in producing a mouse model of Down syndrome and published a paper.

2020.07.10

Trans Chromosomics, Inc. signed a joint research agreement with Otsuka Pharmaceutical Co., Ltd. for the production of fully human antibodies.

2020.03.17

Trans Chromosomics, Inc. concludes a research agreement with Precision Antibody with respect to development of therapeutic monoclonal antibody drug against a new type of coronavirus (COVID-19) using fully human antibody-producing mice.

2020.03.04

Trans Chromosomics, Inc. signed a feasibility research agreement with Shionogi & Co., Ltd. for antibody production using fully human antibody-producing mice.

2020.03.04

Trans Chromosomics, Inc. concludes a tripartite research agreement with Japan’s National Institute of Infectious Diseases and Tottori University with respect to development of therapeutic monoclonal antibody drug against a new type of coronavirus (COVID-19) using fully human antibody-producing mice.

2020.02.27

Development of therapeutic monoclonal antibody drug against a new type of coronavirus (COVID-19) using fully human antibody-producing animals

2019.05.07

Trans Chromosomics, Inc. concludes a joint research agreement with Japan's National Institute of Infectious Diseases with respect to development of human antibodies against pathogenic viruses by utilizing fully human antibody-producing animals.
 

2019.05.07

Trans Chromosomics, Inc. concludes a tripartite research agreement with Japan's National Institute of Infectious Diseases and Tottori University with respect to development of human antibodies against pathogenic viruses and toxins by utilizing fully human antibody-producing animals.

2019.02.20

Trans Chromosomics, Inc. Announces Changes in Top Management.

2018.12.01

Trans Chromosomics, Inc. established the Board of Corporate Auditors.

2018.06.14

Trans Chromosomics, Inc. has Signed MTA with NIH/NIAMS on Fully Human Monoclonal Antibody Producing Mice.

2018.04.24

Attending at 2018 BIO International Convention (Exhibition & Partnering)

2018.01.31

Trans Chromosomics, Inc. Announces Changes in Top Management

2017.11.03

Trans Chromosomics, Inc. Has Signed Feasibility Research Collaboration Agreement with Mitsubishi Tanabe Pharma On Fully Human Monoclonal Antibody Producing Mice/Rats.

 

2017.03.30
Trans Chromosomics, Inc. Has Signed Feasibility Research Collaboration Agreement Including Option Rights with KAN Research Institute Inc. And Eisai Co., Ltd. On Fully Human Monoclonal Antibody Producing Mice/Rats.

 

2017.03.15 

Trans Chromosomics Inc. Has Signed Feasibility Research Collaboration Agreement with Daiichi Sankyo On Fully Human Monoclonal Antibody Producing Mice/Rats

2016.06.22 

English site is available now!!

Our Mission

We contribute to people's living and health by

applying innovative chromosome engineering

technology developed by Tottori University (Japan) to medical treatment and drug discovering widely

bottom of page